ReviewMolecular biotechnology2026
Engineered Extracellular Vesicles for Treatment of Inflammatory Diseases.
Review in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From pathogenic carriers to therapeutic hope: the dual role and translational prospects of exosomes in diabetic kidney disease.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Inflammation-related disorders constitute a major global health challenge, with annual incidence exceeding tens of millions of cases and economic losses surpassing hundreds of billions USD. These burdens significantly impact both healthcare systems and socioeconomic development. Current clinical therapies are limited by suboptimal efficacy, which poses health risks to patients and underscores the demand for innovative therapeutic strategies. Emerging evidence demonstrates that extracellular vesicles (EVs) exhibit significant therapeutic advantages over conventional pharmacological interventions in managing inflammatory disorders. Native EVs possess inherent advantages including superior biocompatibility, structural integrity, and unique biological barrier penetration capacities, positioning them as promising therapeutic agents for inflammatory conditions. Engineered EVs can be functionalized with targeted delivery systems to transport bioactive components, such as miRNAs and proteins, enabling precise modulation of inflammatory signaling pathways. This approach enhances therapeutic efficacy, shortens treatment duration, reduces morbidity rates, and decreases healthcare costs. This review examines the therapeutic potential of EVs in inflammatory diseases and summarizes recent advances in their application to specific inflammatory disorders. We discuss the clinical translation challenges of EVs and highlight their prospects for inflammatory disease therapeutics.
Indexed as
Identifiers
41252109What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.